Molecular mechanisms of sepsis

Contributions to Microbiology

Volumn 17, Issue , 2011, Pages 48-85

  Russell, James A ^a   Boyd, John ^a   Nakada, Taka ^a   Thair, Simone ^a   Walley, Keith R ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL (TOPIC); ENDOCRINE DISEASE; HUMAN; INTENSIVE CARE; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

APOPTOSIS; BLOOD COAGULATION DISORDERS; CLINICAL TRIALS AS TOPIC; ENDOCRINE SYSTEM DISEASES; HUMANS; INTENSIVE CARE; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84926122054     PISSN: 14209519     EISSN: 1662291X     Source Type: Book Series    
DOI: 10.1159/000324009     Document Type: Article

References (143)

1. Thorgersen EB, Pharo A, Haverson K, et al: Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect Immun 2009;77: 725-732.
2. Cavassani KA, Ishii M, Wen H, et al: TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med 2008;205: 2609-2621.
3. Ha T, Lu C, Liu L, et al: TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide 3-kinase-dependent mechanism. Am J Physiol Heart Circ Physiol 2008;298: H984-H991.
4. Raymond T, Schaller M, Hogaboam CM, Lukacs NW, Rochford R, Kunkel SL: Toll-like receptors, Notch ligands, and cytokines drive the chronicity of lung inflammation. Proc Am Thorac Soc 2007;4: 635-641.
5. Weberpals M, Hermes M, Hermann S, et al: NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci 2009;29: 14177-14184.
6. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR: Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006;72:384-393.
7. Davani EY, Boyd JH, Dorscheid DR, et al: Cardiac ICAM-1 mediates leukocyte-dependent decreased ventricular contractility in endotoxemic mice. Cardiovasc Res 2006;72:134-142.
8. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR: S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008;102: 1239-1246.
9. Davani EY, Dorscheid DR, Lee CH, van Breemen C, Walley KR: Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. Am J Physiol Heart Circ Physiol 2004; 287:H1013-H1022.
10. Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ: Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. J Appl Physiol 1994;76:1060-1067.
11. Zarnegar B, Yamazaki S, He JQ, Cheng G: Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008;105:3503-3508.
12. Zarnegar BJ, Wang Y, Mahoney DJ, et al: Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371-1378.
13. Liao G, Zhang M, Harhaj EW, Sun SC: Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-26250.
14. Hu WH, Mo XM, Walters WM, Brambilla R, Bethea JR: TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation. J Biol Chem 2004;279:35975-35983.
15. Yang CH, Murti A, Pfeffer LM: Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J Biol Chem 2005;280:31530-31536.
16. Seymour R, Sundberg JP, Hogenesch H: Abnormal lymphoid organ development in immunodeficient mutant mice. Vet Pathol 2006;43:401-423.
17. Sasaki Y, Calado DP, Derudder E, et al: NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF: BAFF-R-mediated survival signals in B cells. Proc Natl Acad Sci USA 2008;105:10883-10888.
18. Leghmari K, Bennasser Y, Bahraoui E: HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur J Cell Biol 2008;87:947-962.
19. Varfolomeev E, Vucic D: (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 2008;7:1511-1521.
20. Cohen P: Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009;21:317-324.
21. Traeger T, Kessler W, Hilpert A, et al: Selective depletion of alveolar macrophages in polymicrobial sepsis increases lung injury, bacterial load and mortality but does not affect cytokine release. Respiration 2009;77:203-213.
22. O'Sullivan AW, Wang JH, Redmond HP: NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. J Surg Res 2009;152:46-53.
23. van der Poll T, Lowry SF: Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock 1995;3:1-12.
24. Matsukawa A, Hogaboam CM, Lukacs NW, Kunkel SL: Chemokines and innate immunity. Rev Immunogenet 2000;2:339-358.
25. Schmidt C, Hocherl K, Kurt B, Moritz S, Kurtz A, Bucher M: Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine 2010;49:30-38.
26. Bone RC, Sibbald WJ, Sprung CL: The ACCPSCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-1483.
27. Jenner RG, Young RA: Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005;3:281-294.
28. Fan H, Cook JA: Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004;10:71-84.
29. Ogata M, Okamoto K, Kohriyama K, Kawasaki T, Itoh H, Shigematsu A: Role of interleukin-10 on hyporesponsiveness of endotoxin during surgery. Crit Care Med 2000;28:3166-3170.
30. Mantovani A, Locati M, Polentarutti N, Vecchi A, Garlanda C: Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Tolllike receptors: The new entry TIR8/SIGIRR. J Leukoc Biol 2004;75:738-742.
31. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003;4:920-927.
32. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J: Inhibition of interleukin 1 receptor/ Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003;197: 263-268.
33. Zhang G, Ghosh S: Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002;277:7059-7065.
34. Jiang X, Zhu D, Okagaki P, Lipsky R, Wu X, Banaudha K, Mearow K, Strauss KI, Marini AM: N-methyl-D-aspartate and TrkB receptor activation in cerebellar granule cells: An in vitro model of preconditioning to stimulate intrinsic survival pathways in neurons. Ann NY Acad Sci 2003;993: 134-145, discussion 159-160.
35. Tross D, Petrenko L, Klaschik S, Zhu Q, Klinman DM: Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3. Mol Immunol 2009;46:2557-2564.
36. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952-6963.
37. Wiersinga WJ, van't Veer C, van den Pangaart PS, Dondorp AM, Day NP, Peacock SJ, van der Poll T: Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009;37:569-576.
38. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, Ayala A: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA 2009;106:6303-6308.
39. Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A: Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003; 31:2068-2071.
40. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, Volk HD: Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome -a new approach: Proof of principle. Arch Intern Med 1997;157:389-393.
41. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: Restoration by IFNgamma treatment. Nat Med 1997;3:678-681.
42. Murphey ED, Herndon DN, Sherwood ER: Gamma interferon does not enhance clearance of Pseudomonas aeruginosa but does amplify a proinflammatory response in a murine model of postseptic immunosuppression. Infect Immun 2004;72: 6892-6901.
43. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H: Role of Toll-like receptors in the development of sepsis. Shock 2008;29: 315-321.
44. Oberholzer A, Oberholzer C, Moldawer LL: Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock 2001;16:83-96.
45. Nakamura T, Yamagishi SI: PEDF and septic shock. Curr Mol Med 2010;10:312-316.
46. Leone M, Textoris J, Michel F, Wiramus S, Martin C: Emerging drugs in sepsis. Expert Opin Emerg Drugs 2010;15:41-52.
47. Reddy RC, Standiford TJ: Effects of sepsis on neutrophil chemotaxis. Curr Opin Hematol 2010;17: 18-24.
48. van Zoelen MA, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, Nawroth PP, Bierhaus A, Tracey KJ, van der Poll T: Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009;31:280-284.
49. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101:2652-2660.
50. Kim JH, Kim SJ, Lee IS, Lee MS, Uematsu S, Akira S, Oh KI: Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol 2009;182:2458-2466.
51. Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F: Highmobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost 2009;102:352-359.
52. Zheng W, Flavell RA: The transcription factor GATA-3 is necessary and sufficient or Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-596.
53. Guisset O, Dilhuydy MS, Thiebaut R, Lefevre J, Camou F, Sarrat A, Gabinski C, Moreau JF, Blanco P: Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007;33:148-152.
54. Wen H, Dou Y, Hogaboam CM, Kunkel SL: Epigenetic regulation of dendritic cell derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 2008;111: 1797-1804.
55. Pene F, Zuber B, Courtine E, Rousseau C, Ouaaz F, Toubiana J, Tazi A, Mira JP, Chiche JD: Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol 2008;181:8513-8520.
56. Russell, JA: Management of sepsis. N Engl J Med 2006;355:1699-1713.
57. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, Sundin DP: Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. Crit Care 2006;10:R92.
58. Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, Beaudin S, Julian JA, Weitz JI, Crowther M, Loeb M, Cook D: Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004;104:3958-3964.
59. Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979;571:333-342.
60. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984;63:486-489.
61. van Hinsbergh VW, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F: Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985;65:444-451.
62. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344: 699-709.
63. Schuepbach RA, Feistritzer C, Brass LF, Riewald M: Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 2008;111: 2667-2673.
64. Yang L, Bae JS, Manithody C, Rezaie AR: Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J Biol Chem 2007;282:25493-25500.
65. Galley HF, El Sakka NE, Webster NR, Lowes DA, Cuthbertson BH: Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 2008;100:815-819.
66. Sharma GR, Gerlitz B, Berg DT, Cramer MS, Jakubowski JA, Galbreath EJ, Heuer JG, Grinnell BW: Activated protein C modulates chemokine response and tissue injury in experimental sepsis. Adv Exp Med Biol 2008;614:83-91.
67. Gupta A, Rhodes GJ, Berg DT, Gerlitz B, Molitoris BA, Grinnell BW: Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007;293:F245-F254.
68. Yesilirmak DC, Kumral A, Tugyan K, Cilaker S, Baskin H, Yilmaz O, Duman N, Ozkan H: Effects of activated protein C on neonatal hypoxic ischemic brain injury. Brain Res 2008;1210:56-62.
69. Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F: Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: A cohort study in septic shock patients. Crit Care Med 2007;35: 69-75.
70. Minhas N, Xue M, Fukudome K, Jackson CJ: Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. Faseb J 2009;24:873-881.
71. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H: Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007;204:2439-2448.
72. Mosnier LO, Yang XV, Griffin JH: Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007;282: 33022-33033.
73. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Baruch D: Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35:2375-2382.
74. Lerolle N, Dunois-Larde C, Badirou I, Motto DG, Hill G, Bruneval P, Diehl JL, Denis CV, Baruch D: Von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. J Thromb Haemost 2009;7:843-850.
75. Lupia E, Bosco O, Mariano F, Dondi AE, Goffi A, Spatola T, Cuccurullo A, Tizzani P, Brondino G, Stella M, Montrucchio G: Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation. J Thromb Haemost 2009;7:1000-1008.
76. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006;6:813-822.
77. Hotchkiss RS, et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-1251.
78. Hotchkiss RS, et al: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952-6963.
79. Hotchkiss RS, et al: Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002;168:2493-2500.
80. Le Tulzo Y, et al: Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002;18:487-494.
81. Wesche-Soldato DE, et al: In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005;106:2295-2301.
82. Inoue S, et al: IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2001;184: 1401-1409.
83. Jimenez MF, et al: Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 1997;132: 1263-1269.
84. Keel M, et al: Interleukin-10 counterregulates proinflammatory cytokine induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997;90: 3356-3363.
85. Taneja R, et al: Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity. Crit Care Med 2004;32:1460-1469.
86. Jia SH, Parodo J, Kapus A, Rotstein OD, Marshall JC: Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase 8. J Biol Chem 2008;283: 5402-5413.
87. Guo RF, et al: In vivo regulation of neutrophil apoptosis by C5a during sepsis. J Leukoc Biol 2006;80: 1575-1583.
88. Albertine KH, et al: Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 2002;161: 1783-1796.
89. Matsuda N, et al: Silencing of fas-associated death domain protects mice from septic lung inflammation and apoptosis. Am J Respir Crit Care Med 2009;179:806-815.
90. Coopersmith CM, et al: Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med 2002;30:195-201.
91. Coopersmith CM, et al: Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002;287: 1716-1721.
92. Stromberg PE, et al: CD4+ lymphocytes control gut epithelial apoptosis and mediate survival in sepsis. FASEB J 2009;23:1817-1825.
93. Charmandari E, Tsigos C, Chrousos G: Endocrinology of the stress response. Annu Rev Physiol 2005;67:259-284.
94. Marik PE, Zaloga GP: The central nervous system hypothalamic-pituitary- adrenal axis in sepsis. Crit Care Med 2002;30:490-491.
95. McCann SM, Kimura M, Karanth S, Yu WH, Mastronardi CA, Rettori V: The mechanism of action of cytokines to control the release of hypothalamic and pituitary hormones in infection. Ann NY Acad Sci 2000;917:4-18.
96. Sharshar T, Annane D, de la Grandmaison GL, Brouland JP, Hopkinson NS, Francoise G: The neuropathology of septic shock. Brain Pathol 2004;14: 21-33.
97. Brent GA, Hershman JM: Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986;63:1-8.
98. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341: 785-792.
99. Stathatos N, Levetan C, Burman KD, Wartofsky L: The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab 2001;15:465-478.
100. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
101. Annane D, Sebille V, Bellissant E: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006;34:22-30.
102. Holmes CL, Patel BM, Russell JA, Walley KR: Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
103. Holmes CL, Landry DW, Granton JT: Science review: Vasopressin and the cardiovascular system part 1 -receptor physiology. Crit Care 2003;7:427-434.
104. Holmes CL, Landry DW, Granton JT: Science Review: Vasopressin and the cardiovascular system part 2 -clinical physiology. Crit Care 2004;8:15-23.
105. Boyd J: Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 2008;79:325-331.
106. Landry DW, Oliver JA: The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992;89: 2071-2074.
107. Noguera I, Medina P, Segarra G, Martinez MC, Aldasoro M, Vila JM, Lluch S: Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br J Pharmacol 1997;122: 431-438.
108. Bucher M, Hobbhahn J, Taeger K, Kurtz A: Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002;282: R979-R984.
109. Roth BL, Spitzer JA: Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 1987;252: E699-E702.
110. Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G: Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 2004;65:54-62.
111. Qahwash IM, Cassar CA, Radcliff RP, Smith GW: Bacterial lipopolysaccharide induced coordinate downregulation of arginine vasopressin receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers. Endocrine 2002;18:13-20.
112. Schmidt C, Hocherl K, Kurt B, Bucher M: Role of nuclear factor-kappaB-dependent induction of cytokines in the regulation of vasopressin V1Areceptors during cecal ligation and punctureinduced circulatory failure. Crit Care Med 2008;36: 2363-2372.
113. Indrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR: Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. Crit Care 2009;13:R98.
114. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125.
115. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D: Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-1758.
116. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D: Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497-500.
117. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
118. Russell JA, Walley KR: Vasopressin and its immune effects in septic shock. J Innate Immun 2010;2: 446-460.
119. Zhao L, Brinton RD: Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: A cAMP response element-binding protein-dependent mechanism. J Neurosci 2004;24: 2226-2235.
120. Chassin C, Hornef MW, Bens M, et al: Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med 2007;204:2837-2852.
121. Banisadr G, Skrzydelski D, Kitabgi P, Rostene W, Parsadaniantz SM: Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: Constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur J Neurosci 2003;18:1593-1606.
122. Fleisher-Berkovich S, Kagan E, Grossman N, Danon A: Multiple effects of arginine vasopressin on prostaglandin E2 synthesis in fibroblasts. Eur J Pharmacol 2004;485:53-59.
123. Baker C, Richards LJ, Dayan CM, Jessop DS: Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: Colocalization with arginine vasopressin. J Neuroendocrinol 2003;15:1070-1074.
124. Geenen V, Defresne MP, Robert F, Legros JJ, Franchimont P, Boniver J: The neurohormonal thymic microenvironment: Immunocytochemical evidence that thymic nurse cells are neuroendocrine cells. Neuroendocrinology 1988;47:365-368.
125. Jessop DS, Chowdrey HS, Lightman SL, Larsen PJ: Vasopressin is located within lymphocytes in the rat spleen. J Neuroimmunol 1995;56:219-223.
126. Chowdrey HS, Lightman SL, Harbuz MS, Larsen PJ, Jessop DS: Contents of corticotropin-releasing hormone and arginine vasopressin immunoreactivity in the spleen and thymus during a chronic inflammatory stress. J Neuroimmunol 1994;53:17-21.
127. Bell J, Adler MW, Greenstein JI: The effect of arginine vasopressin on the autologous mixed lymphocyte reaction. Int J Immunopharmacol 1992;14: 93-103.
128. Hu SB, Zhao ZS, Yhap C, et al: Vasopressin receptor 1a-mediated negative regulation of B cell receptor signaling. J Neuroimmunol 2003;135:72-81.
129. Russell JA, Walley KR, Gordon AC, et al: Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37:811-818.
130. Pietranera L, Saravia F, Roig P, Lima A, De Nicola AF: Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats. Neuroendocrinology 2004; 80:100-110.
131. Ertmer C, Bone HG, Morelli A, et al: Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007;27: 281-288.
132. Rabadan-Diehl C, Aguilera G: Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998;139:3220-3226.
133. Tanoue A, Ito S, Honda K, et al: The vasopressin V1b receptor critically regulates hypothalamicpituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004;113:302-309.
134. Aguilera G, Rabadan-Diehl C: Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation. Regul Pept 2000;96:23-29.
135. Mesotten D, Wouters PJ, Peeters RP, Hardman KV, Holly JM, Baxter RC, Van den Berghe G: Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. J Clin Endocrinol Metab 2004;89:3105-3113.
136. Ross RJ, Rodriguez-Arnao J, Bentham J, Coakley JH: The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill. Intensive Care Med 1993;19(suppl 2):S54-S57.
137. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R: The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002;56:655-669.
138. Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R et al: Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998;83:309-319.
139. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R et al: The somatotropic axis in critical illness: Effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 1997;82:590-599.
140. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C: Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991;35:47-54.
141. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341: 785-792.
142. Ruokonen E, Takala J: Dangers of growth hormone therapy in critically ill patients. Curr Opin Clin Nutr Metab Care 2002;5:199-209.
143. Polito A, Aboab J, Annane D: The hypothalamic pituitary adrenal axis in sepsis. Novartis Found Symp 2007;280:182-199, discussion 199-203.